Veru (NASDAQ:VERU) Stock Passes Below 200 Day Moving Average – Here’s Why

Shares of Veru Inc. (NASDAQ:VERU) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.81 and traded as low as $0.64. Veru shares last traded at $0.68, with a volume of 1,431,955 shares trading hands.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Oppenheimer reiterated an “outperform” rating and issued a $5.00 target price on shares of Veru in a research note on Tuesday, November 5th. HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of Veru in a research note on Friday, December 20th.

Veru Stock Down 1.3 %

The company has a market capitalization of $98.93 million, a PE ratio of -1.41 and a beta of -0.50. The business has a 50 day simple moving average of $0.72 and a 200 day simple moving average of $0.81.

Veru (NASDAQ:VERU) last posted its quarterly earnings data on Monday, December 16th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. Veru had a negative net margin of 376.38% and a negative return on equity of 115.99%. Equities analysts expect that Veru Inc. will post -0.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Zacks Investment Management acquired a new position in shares of Veru in the 3rd quarter valued at $25,000. Gladstone Institutional Advisory LLC increased its holdings in shares of Veru by 34.2% in the third quarter. Gladstone Institutional Advisory LLC now owns 56,876 shares of the company’s stock valued at $44,000 after purchasing an additional 14,500 shares during the period. SG Americas Securities LLC raised its stake in shares of Veru by 185.9% in the third quarter. SG Americas Securities LLC now owns 66,128 shares of the company’s stock worth $51,000 after purchasing an additional 42,997 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of Veru by 142.8% during the third quarter. Jane Street Group LLC now owns 96,454 shares of the company’s stock worth $74,000 after purchasing an additional 56,736 shares during the period. Finally, Rhumbline Advisers boosted its position in Veru by 3,994.8% in the second quarter. Rhumbline Advisers now owns 113,632 shares of the company’s stock valued at $96,000 after buying an additional 110,857 shares during the last quarter. Hedge funds and other institutional investors own 47.16% of the company’s stock.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.